Catalyst
Slingshot members are tracking this event:
Celgene Releases Interim Analyses on Endpoints in Phase 3 ABOUND Study of ABRAXANE on Patients with Non-Small Cell Lung Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
CELG |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Interim Analysis, Abound Study, Abraxane, Non-small Cell Lung Cancer